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ABSTRACT 
Hepatitis B is significant health problems that might involve the late sequel of liver cirrhosis and 
hepatocellular carcinoma. The present study aimed to know the seroprevalence of hepatitis B virus (HBV) in 
mid and far western region in Nepal with various clinical conditions.  
This was a retrospective study conducted in mid and far western region in Nepal, which was 
performed in the Central Laboratory of Microbiology at Nepalgunj Medical College and Teaching Hospital, 
Banke, Nepal during the period of September 2010 to April 2012. The serum samples were tested for 
Hepatitis B surface Antigen (HBsAg) by Sandwich immunoassay. Total 7010 patients including 43.72% male 
and 56.28% female  were tested for HBsAg. Of them, 135 were positive and 6875 were negative.  
In 135 positive cases 84 (62.22%) were male and 51 (37.77% )were female. In 6875 negative cases 
2981 were male and 3894 were female. The seroprevalence rate of HBV was 1.93% in mid and far western 
region in Nepal. Seroprevalence of HBV seems to be higher in male then the female; it was 2.75% in male 
and 1.29% in female.  
The study revealed that the seroprevalence of HBV was alarmingly higher in such a population, 
which probably reflects a high background prevalence of HBV infections should be taken into consideration 
and Implementation of community-based preventive measures and improved strategies for safe blood 
supply might prove useful to decrease the seroprevalence. 
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INTRODUCTION 
There is high global prevalence of hepatitis-B. 
The Hepatitis-B virus (HBV) was discovered by  Baruch 
Blumberg, he discovered the Australia antigen 
(Hepatitis B surface antigen, or HBsAg) in the blood of 
Australian aboriginal people in 1965.
1 
Approximately, 
there are one-third of the world population has 
serological evidence of the past or present Hepatitis-B 
virus (HBV) infection, resulting in 350 million 
chronically infected people.
2
 And over 1 million die 
annually of HBV-related chronic liver disease. 
Although many individuals eventually achieve a state 
of non-replicative infection, the prolonged 
immunologic response to infection leads to the 
development of cirrhosis, liver failure, or 
hepatocellular carcinoma (HCC) in up to 40% of 
patients.
3
 In Nepal, seroprevalence of HBsAg has been 
reported ranging from 0.3% to 4.0% in general 
population by various studies conducted from 1990 to  
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 The presence of HBsAg, the main surface 
protein of HBV, in serum
 
indicates infection. Persistent 
presence of Hepatitis B surface antigen (HBsAg) for at 
least six months defines the chronic hepatitis B (CHB) 
carrier state.Conventionally, presence of secretory 
version of HBV core protein, the e antigen (HBeAg) , 
associated with high viral load and serves as a marker 
for viral replication.
11
 After the initial characterization 
of HBeAg
 
, a truncated form of the core (nucleocapsid) 
protein, all
 
patients with both HBsAg and HBeAg are 
considered highly infectious.
12 
HBeAg serconversion 
(HBeAg negative and anti HBe) is associated with liver 
disease remission and marks the transition from 
chronic Hepatitis B to asymptomatic HBsAg carrier 
state. At the time of  HBeAg seroconversion, a small 
percentage of patients continue to show raised 
Alanine aminotransferase(ALT) and serum  HBV DNA 
levels.
11 
this group of patients is called as HBeAg 
negative chronic hepatitis B (CHB) which continues to 
have liver damage but due to frequent changes of ALT 
levels, become difficult to differentiate from inactive 
carriers.
13,14
 Viral load quantification by PCR plays a 
vital role in the better management of this dreadful 
pathogen as diagnosis of different stages of HBV  
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infection can be defined by serum HBV DNA levels 
especially in differentiating HBeAg negative CHB 
patients from inactive carriers.
15
 
 
MATERIALS AND METHODS 
Serum samples were collected from 7010 
patients between the periods of September 2010 
to April 2012. Samples were collected in clean, 
sterile, small test tube from suspected HBV 
infections and its sequelae patients attending 
out-patients and in-patients departments at 
Microbiology Laboratory of Nepalgunj College 
Medical & Teaching Hospital in Banke, Nepal. All 
the serum samples were tested by Virucheck- 
HBsAg kit (Orchid Biomedical system, Goa, India). 
The instructions, test procedure, reagents and 
accessories to follow were supplied with the kit. 
 
RESULTS 
Total 7010 patients were included in this study. 
43.72% male and 56.28% female were tested for 
HBsAg (Figure 1). 
 
 
 
Figure.1  
Sex Distribution of Cases 
 
In this study, it was observed that 135 were positive 
and 6875 were negative. In 135 positive cases 84 were 
male and 51 were female. In 6875 negative cases 2981 
were male and 3894 were female. Highest positive 
case were found in the age group of 21- 30 (Table 1 
and Figure 2). 
The seroprevalence of total case was 1.93%. 
Seroprevalence of total female was 1.29% and the 
seroprevalence of total male was 2.74% (Table 2). The 
highest seroprevalence of male found in the age group 
21–30 was 4.53 and the highest seroprevalence of 
female found in the age group 0–10  was 5.37  (Table 3 
and Figure 3). 
 
 
 
 
 
Table 1 
Seroprevalence of HBV According to Age Group Wise 
Distribution 
 
Age 
HBsAg 
Total 
seroprevalence 
rate (%) Positive Negative 
0-10 12 472 484 2.58 
11-20 4 1059 1063 0.38 
21-30 49 1836 1885 2.60 
31-40 16 1279 1295 1.24 
41-50 23 927 950 2.42 
51-60 11 634 645 1.71 
61-70 14 412 426 3.29 
> 70 6 256 262 2.29 
Total 135 6875 7010 1.93 
 
 
 
 
Figure.2 
Age group wise distribution of total positive case. 
 
 
Table 2 
Sex Wise Seroprevalence of all Cases 
 
Sex 
HBsAg 
Total 
Sero 
prevalence 
rate (%) Positive Negative 
Male 84 2981 3065 
(43.72%) 
2.74 
Female 51 3894 3945 
(56.28%) 
1.29 
Total 135 6875 7010 
(100%) 
1.93 
 
DISCUSSION 
The hepatitis B occurs throughout the world. It 
has no seasonal distribution. In the developed 
countries, the incidence is more in adults than in 
children and more in urban than in rural areas.  
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Table 3 
Seroprevalence of HBV According to Sex Wise 
Distribution in different Age Groups. 
 
Age 
Sex 
Male Female 
0-10 0.67 5.37 
11-20 0.59 0.27 
21-30 4.53 1.25 
31-40 1.50 1.04 
41-50 3.16 1.77 
51-60 2.85 0.60 
61-70 3.63 2.91 
> 70 3.94 00.00 
Total 2.74 1.29 
 
 
However, in Africa and the Far East, where it is 
transmitted from mother to offspring or through close 
personal contact, it is more common in infants and 
children. In endemic areas, where carrier rates are 
>5%, most individuals are infected perinatally, by 
vertical transmission, or in early childhood.
16
 
 
 
 
Figure 3  
The comparative seroprevalence of male & female in 
different age group. 
 
The carrier rate is higher in the tropical than in the 
temperate regions, more in males than in females. 
HBV is present in blood, saliva, semen, vaginal 
secretions and menstrual blood of infected individuals. 
Because HBV is resistant to breakdown outside the 
body, it is easily transmitted through contact with 
infected bodily fluids17. Perinatal vertical transmission 
is the most common mode of transmission worldwide. 
Presence of HBV e antigen (HBeAg) in the mother’s 
serum is associated with greater infectivity18,19.The 
risk of perinatal HBV infection among infants born to 
HBV-infected mothers ranges from 10–40% in HBeAg  
 
negative mothers to 70–90% in HBeAg-positive 
mothers20. Children of HBsAg-positive mothers who 
do not become infected perinatally remain at high risk 
of infection during early childhood. In households of a 
chronically infected individual, HBV infection can occur 
via person-to-person, nonsexual contact20. 
Transmission is mainly by the percutaneous route. 
Besides blood transfusion, a number of therapeutic, 
prophylactic and diagnostic procedures can convey 
the infection. The virus is highly infectious and very 
minute amounts of some carrier sera (as little as 
0.00001 ml) can transmit the disease. Therefore, any 
procedure that can convey traces of blood or serum 
from one person to another can serve to spread the 
infection. The disease is particularly common among 
drug addicts, prostitutes and male homosexuals. 
Certain groups and occupations carry a high risk of 
developing infection. These include medical and  
 
paramedical personnel, staff of blood banks and 
hemodialysis units, laboratory worker and staff of 
institutions for the mentally retarded. Outbreaks have 
occurred in hospital staff and patients.
21
 
In this study, The seroprevalence rate of HBV was 
1.93% in mid and far western region in Nepal. The 
seroprevalence of HBV seems to be higher in male 
then the female; it was 2.75% in male and 1.29% in 
female.The age specific seroprevalence in this study 
was also found to be higher (2.60%) in 21-30 year age 
groups. 
 
CONCLUSION 
This study shows that seroprevalence of viral 
hepatitis B was 1.93% and most commonly observed 
in males. The incidence is higher in adult age groups. 
Since there is no specific treatment, prevention has 
been the major aim in managing viral hepatitis B. Both 
pre-exposure and post-exposure administration of 
hepatitis B vaccine has been recommended. The policy 
to give pre-exposure prophylaxis to general 
population should be adopted as soon as possible, to 
prevent it emerging as a public health problem. 
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